美國配藥藥房市場2022-2030：市場規模（藥房類型/滅菌類別/產品/應用/配藥類型/治療區域）/增長潛力/價格趨勢/市場份額/預測

U.S. Compounding Pharmacies Market Size By Pharmacy Type, By Sterility, By Product, By Application, By Compounding Type, By Therapeutic Area, Industry Analysis Report, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2030

出版日期: 2022年06月30日 | 出版商:

Global Market Insights Inc. | 英文 101 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

由於對個性化醫療的接受度提高，預計美國配藥市場將在 2030 年之前呈現強勁增長勢頭。

此外，美國藥品日益短缺和配藥的供應預計將在預測期內加速市場擴張。

由於獸醫診所配藥的採用率不斷上升，預計獸醫部門在預測區間內的複合年增長率將超過 5.1%。按產品劃分，由於可以用鼻腔製劑輕鬆治療的耳鼻喉科疾病的增加，預計鼻部部門在預測期內的複合年增長率約為 5.5%。

本報告調查了美國配藥藥房市場，定義和概述了市場，分析了對市場增長、法律和監管/贖回環境、市場規模變化/預測以及各個類別的各種影響因素。它總結了主要公司的細分、競爭環境、概況等。

策略儀表板
Athenex Pharma Solutions(Athenex Inc.)
B Braun Melsungen AG
Clinigen Group PLC
Dougherty's Pharmacy, Inc.
Fagron
Fresenius Kabi
ImprimisRx(Harrow Health, Inc.)
Institutional Pharmacy Solutions
ITC Compounding Pharmacy
Lorraine's Pharmacy
McGuff Company Inc(McGuff Compounding Pharmacy Services)
Nephron Pharmaceuticals Corporation
Pencol Compounding Pharmacy
QuVa Pharma
Rx3 Compounding Pharmacy
Triangle Compounding Pharmacies
Wedgewood Village Pharmacy, Inc.

簡介目錄圖表

Product Code: 2961

The U.S. compounding pharmacies market is set to witness robust growth through 2030 owing to increasing acceptance of personalized medicines. In addition, easy availability of compounded drugs, along with prevalent drug shortage in the U.S., is also expected to spur market expansion over the forecast timeframe.

Notably, industry players have been adopting profitable strategies to improve their business presence, enhancing overall market dynamics. For instance, in March 2022, Medisca, a supplier of pharmaceutical equipment and ingredients, inked an agreement with SUANFARMA, a European distributor and manufacturer of pharmaceutical ingredients, for the global distribution and supply of Thyroid Powder, USP, for which it leveraged its partnership with Deebio, a pharmaceutical manufacturer.

The U.S. compounding pharmacies market has been bifurcated in terms of application, product, pharmacy type, sterility, compounding type, and therapeutic area. Based on application, the market has been segmented into adult, veterinary, geriatric, and pediatric. Owing to rising adoption rates of compounded medication by veterinary clinics, the veterinary sub-segment is set to depict a CAGR of more than 5.1% between 2022 and 2030.

On the basis of product, the U.S. compounding pharmacies market has been divided into topical, parenteral, nasal, otic, ophthalmic, rectal, and oral. The nasal sub-segment is foreseen to expand at a CAGR of about 5.5% over the forecast timeframe driven by increasing occurrences of ENT disorders that can be treated easily with nasal compounded medications. Additionally, the ease of usage of compounded nasal drops is likely to aid segmental growth.

With respect to pharmacy type, the market has been branched into 503A and 503B. The 503B sub-segment garnered a market share of over 56.5% in 2021 owing to a surge in drug shortages in the U.S., coupled with mounting preference for outsourcing facilities for manufacturing drugs that are in short supply.

By sterility, the U.S. compounding pharmacies market has been fragmented into non-sterile and sterile. In 2021, the non-sterile sub-segment was valued at more than $3.7 billion due to several benefits of non-sterile compounded medications, such as easy availability, self-administration, and personalized route of administration.

With regards to compounding type, the market has been segregated into unavailable pharmaceutical manufacturing (CUPM), pharmaceutical ingredient alteration (PIA), currently pharmaceutical dosage alteration (PDA), and others. The currently unavailable pharmaceutical manufacturing (CUPM) sub-segment held a market share of about 22.8% in 2021 on account of surging incidences of drug shortage across the U.S. In addition, compounded pharmacies play a vital role in curbing drug shortages, which is primed to supplement segmental development.

From the perspective of therapeutic area, the U.S. compounding pharmacies market has been categorized into nutritional supplements, dermatology, hormone replacement, pain management, specialty drugs, and others. In 2021, the specialty drugs sub-segment held around 9.6% market share supported by the ease of formulation of specialty drugs by compounding pharmacies, coupled with rising interest in personalized medicine to predict, diagnose, and treat diseases.

Chapter 1 Methodology

1.1 Market definitions
1.2 Base estimates & working
1.3 Forecast parameters
1.4 Data validation
1.5 Data sources
- 1.5.1 Secondary
  - 1.5.1.1 Paid sources
  - 1.5.1.2 Unpaid sources
- 1.5.2 Primary

Chapter 2 Executive Summary

2.1 U.S. compounding pharmacies industry 360 degree synopsis, 2017 - 2030

Chapter 3 US Compounding Pharmacies Industry Insights

3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2030 (USD Million)
3.3 Industry impact forces
- 3.3.1 Growth drivers
  - 3.3.1.1 Increasing geriatric population and improved longevity
  - 3.3.1.2 Growing acceptance of personalized medicines in U.S.
  - 3.3.1.3 Increasing drug shortage in the country
  - 3.3.1.4 Convenience of using compounded drugs
  - 3.3.1.5 Growing demand for compounded bioidentical menopausal hormone therapy (BMHT) among women
- 3.3.2 Restraints
  - 3.3.2.1 Issues related to safety standards of compounded drugs
  - 3.3.2.2 Changing regulatory scenario
3.4 Growth potential analysis
- 3.4.1 By pharmacy type
- 3.4.2 By sterility
- 3.4.3 By product
- 3.4.4 By application
- 3.4.5 By compounding type
- 3.4.6 By therapeutic area
3.5 COVID-19 impact analysis
3.6 Regulatory landscape
3.7 Reimbursement landscape
3.8 Porter's analysis
3.9 Competitive landscape, 2021
3.10 PESTEL analysis

Chapter 4 US Compounding Pharmacies Market, By Pharmacy Type

4.1 Key segment trends
4.2 503A
- 4.2.1 Market size, by 503A, 2017-2030 (USD Million)
4.3 503B
- 4.3.1 Market size, by 503B, 2017-2030 (USD Million)

Chapter 5 US Compounding Pharmacies Market, By Sterility

5.1 Key segment trends
5.2 Sterile
- 5.2.1 Market size, by sterile, 2017-2030 (USD Million)
5.3 Non-sterile
- 5.3.1 Market size, by non-sterile, 2017-2030 (USD Million)

Chapter 6 US Compounding Pharmacies Market, By Product

6.1 Key segment trends
6.2 Oral
- 6.2.1 Market size, by oral, 2017-2030 (USD Million)
- 6.2.2 Solid preparation
  - 6.2.2.1 Market size, by solid preparation, 2017-2030 (USD Million)
  - 6.2.2.2 Tablets
    - 6.2.2.2.1 Market size, by tablets, 2017 - 2030 (USD Million)
  - 6.2.2.3 Capsules
    - 6.2.2.3.1 Market size, by capsules, 2017 - 2030 (USD Million)
  - 6.2.2.4 Granules
    - 6.2.2.4.1 Market size, by granules, 2017 - 2030 (USD Million)
  - 6.2.2.5 Powder
    - 6.2.2.5.1 Market size, by powder, 2017 - 2030 (USD Million)
  - 6.2.2.6 Others
    - 6.2.2.6.1 Market size, by others, 2017 - 2030 (USD Million)
- 6.2.3 Liquid preparation
  - 6.2.3.1 Market size, by liquid preparation, 2017-2030 (USD Million)
  - 6.2.3.2 Solutions
    - 6.2.3.2.1 Market size, by solutions, 2017 - 2030 (USD Million)
  - 6.2.3.3 Suspension
    - 6.2.3.3.1 Market size, by suspension, 2017 - 2030 (USD Million)
  - 6.2.3.4 Emulsion
    - 6.2.3.4.1 Market size, by emulsion, 2017 - 2030 (USD Million)
  - 6.2.3.5 Syrup
    - 6.2.3.5.1 Market size, by syrup, 2017 - 2030 (USD Million)
  - 6.2.3.6 Others
    - 6.2.3.6.1 Market size, by others, 2017 - 2030 (USD Million)
- 6.2.4 Topical
  - 6.2.4.1 Market size, by topical, 2017-2030 (USD Million)
  - 6.2.4.2 Creams
    - 6.2.4.2.1 Market size, by creams, 2017 - 2030 (USD Million)
  - 6.2.4.3 Gels
    - 6.2.4.3.1 Market size, by gels, 2017 - 2030 (USD Million)
  - 6.2.4.4 Pastes
    - 6.2.4.4.1 Market size, by pastes, 2017 - 2030 (USD Million)
  - 6.2.4.5 Ointments
    - 6.2.4.5.1 Market size, by ointments, 2017 - 2030 (USD Million)
  - 6.2.4.6 Others
    - 6.2.4.6.1 Market size, by others, 2017 - 2030 (USD Million)
- 6.2.5 Rectal
  - 6.2.5.1 Market size, by rectal, 2017-2030 (USD Million)
  - 6.2.5.2 Suppositories
    - 6.2.5.2.1 Market size, by suppositories, 2017 - 2030 (USD Million)
  - 6.2.5.3 Enemas
    - 6.2.5.3.1 Market size, by enemas, 2017 - 2030 (USD Million)
  - 6.2.5.4 Others
    - 6.2.5.4.1 Market size, by others, 2017 - 2030 (USD Million)
- 6.2.6 Parenteral
  - 6.2.6.1 Market size, by parenteral, 2017-2030 (USD Million)
  - 6.2.6.2 Small volume parenteral (SVP) solutions
    - 6.2.6.2.1 Market size, by small volume parenteral (SVP) solutions, 2017 - 2030 (USD Million)
  - 6.2.6.3 Large volume parenteral (LVP) solutions
    - 6.2.6.3.1 Market size, by large volume parenteral (SVP) solutions, 2017 - 2030 (USD Million)
- 6.2.7 Nasal
  - 6.2.7.1 Market size, by nasal, 2017-2030 (USD Million)
- 6.2.8 Ophthalmic
  - 6.2.8.1 Market size, by ophthalmic, 2017-2030 (USD Million)
- 6.2.9 Otic
  - 6.2.9.1 Market size, by otic, 2017-2030 (USD Million)

Chapter 7 US Compounding Pharmacies Market, By Application

7.1 Key segment trends
7.2 Pediatric
- 7.2.1 Market size, by pediatric, 2017-2030 (USD Million)
7.3 Adult
- 7.3.1 Market size, by adult, 2017-2030 (USD Million)
7.4 Geriatric
- 7.4.1 Market size, by geriatric, 2017-2030 (USD Million)
7.5 Veterinary
- 7.5.1 Market size, by veterinary, 2017-2030 (USD Million)

Chapter 8 US Compounding Pharmacies Market, By Compounding Type

8.1 Key segment trends
8.2 Pharmaceutical Ingredient Alteration (PIA)
- 8.2.1 Market size, by pharmaceutical ingredient alteration (PIA), 2017-2030 (USD Million)
8.3 Currently Unavailable Pharmaceutical Manufacturing (CUPM)
- 8.3.1 Market size, by currently unavailable pharmaceutical manufacturing (CUPM), 2017-2030 (USD Million)
8.4 Pharmaceutical Dosage Alteration (PDA)
- 8.4.1 Market size, by pharmaceutical dosage alteration (PIA), 2017-2030 (USD Million)
8.5 Others
- 8.5.1 Market size, by others, 2017-2030 (USD Million)

Chapter 9 US Compounding Pharmacies Market, By Therapeutic Area

9.1 Key segment trends
9.2 Hormone replacement
- 9.2.1 Market size, by hormone replacement, 2017-2030 (USD Million)
9.3 Pain management
- 9.3.1 Market size, by pain management, 2017-2030 (USD Million)
9.4 Dermatology
- 9.4.1 Market size, by dermatology, 2017-2030 (USD Million)
9.5 Specialty drugs
- 9.5.1 Market size, by specialty drugs, 2017-2030 (USD Million)
9.6 Nutritional supplements
- 9.6.1 Market size, by nutritional supplements, 2017-2030 (USD Million)
9.7 Others
- 9.7.1 Market size, by others, 2017-2030 (USD Million)

Chapter 10 Company Profiles

10.1 Strategy dashboard, 2021
10.2 Athenex Pharma Solutions (Athenex Inc.)
- 10.2.1 Business overview
- 10.2.2 Financial data
- 10.2.3 Product landscape
- 10.2.4 Strategic outlook
- 10.2.5 SWOT analysis
10.3 B Braun Melsungen AG
- 10.3.1 Business overview
- 10.3.2 Financial data
- 10.3.3 Product landscape
- 10.3.4 SWOT analysis
10.4 Clinigen Group PLC
- 10.4.1 Business overview
- 10.4.2 Financial data
- 10.4.3 Product landscape
- 10.4.4 Strategic outlook
- 10.4.5 SWOT analysis
10.5 Dougherty's Pharmacy, Inc.
- 10.5.1 Business overview
- 10.5.2 Financial data
- 10.5.3 Product landscape
- 10.5.4 SWOT analysis
10.6 Fagron
- 10.6.1 Business overview
- 10.6.2 Financial data
- 10.6.3 Product landscape
- 10.6.4 Strategic outlook
- 10.6.5 SWOT analysis
10.7 Fresenius Kabi
- 10.7.1 Business overview
- 10.7.2 Financial data
- 10.7.3 Product landscape
- 10.7.4 Strategic outlook
- 10.7.5 SWOT analysis
10.8 ImprimisRx (Harrow Health, Inc.)
- 10.8.1 Business overview
- 10.8.2 Financial data
- 10.8.3 Product landscape
- 10.8.4 Strategic outlook
- 10.8.5 SWOT analysis
10.9 Institutional Pharmacy Solutions
- 10.9.1 Business overview
- 10.9.2 Financial data
- 10.9.3 Product landscape
- 10.9.4 Strategic outlook
- 10.9.5 SWOT analysis
10.10 ITC Compounding Pharmacy
- 10.10.1 Business overview
- 10.10.2 Financial data
- 10.10.3 Product landscape
- 10.10.4 Strategic outlook
- 10.10.5 SWOT analysis
10.11 Lorraine's Pharmacy
- 10.11.1 Business overview
- 10.11.2 Financial data
- 10.11.3 Product landscape
- 10.11.4 Strategic outlook
- 10.11.5 SWOT analysis
10.12 McGuff Company Inc (McGuff Compounding Pharmacy Services)
- 10.12.1 Business overview
- 10.12.2 Financial data
- 10.12.3 Product landscape
- 10.12.4 Strategic outlook
- 10.12.5 SWOT analysis
10.13 Nephron Pharmaceuticals Corporation
- 10.13.1 Business overview
- 10.13.2 Financial data
- 10.13.3 Product landscape
- 10.13.4 Strategic outlook
- 10.13.5 SWOT analysis
10.14 Pencol Compounding Pharmacy
- 10.14.1 Business overview
- 10.14.2 Financial data
- 10.14.3 Product landscape
- 10.14.4 Strategic outlook
- 10.14.5 SWOT analysis
10.15 QuVa Pharma
- 10.15.1 Business overview
- 10.15.2 Financial data
- 10.15.3 Product landscape
- 10.15.4 Strategic outlook
- 10.15.5 SWOT analysis
10.16 Rx3 Compounding Pharmacy
- 10.16.1 Business overview
- 10.16.2 Financial data
- 10.16.3 Product landscape
- 10.16.4 Strategic outlook
- 10.16.5 SWOT analysis
10.17 Triangle Compounding Pharmacies
- 10.17.1 Business overview
- 10.17.2 Financial data
- 10.17.3 Product landscape
- 10.17.4 Strategic outlook
- 10.17.5 SWOT analysis
10.18 Wedgewood Village Pharmacy, Inc.
- 10.18.1 Business overview
- 10.18.2 Financial data
- 10.18.3 Product landscape
- 10.18.4 Strategic outlook
- 10.18.5 SWOT analysis

簡介目錄圖表

Data Tables

TABLE 1 U.S. Compounding Pharmacies market, 2017 - 2021 (USD Million)
TABLE 2 U.S. Compounding Pharmacies market, 2022 - 2030 (USD Million)
TABLE 3 Industry impact forces
TABLE 4 U.S. compounding pharmacies market size, by pharmacy type, 2017 - 2021 (USD Million)
TABLE 5 U.S. compounding pharmacies market size, by pharmacy type, 2022 - 2030 (USD Million)
TABLE 6 U.S. compounding pharmacies market size market, by sterility, 2017 - 2021 (USD Million)
TABLE 7 U.S. compounding pharmacies market size, by sterility, 2022 - 2030 (USD Million)
TABLE 8 U.S. compounding pharmacies market size, by product, 2017 - 2021 (USD Million)
TABLE 9 U.S. compounding pharmacies market size, by product, 2022 - 2030 (USD Million)
TABLE 10 U.S. compounding pharmacies market size, by oral, 2017 - 2021 (USD Million)
TABLE 11 U.S. compounding pharmacies market size, by oral, 2022 - 2030 (USD Million)
TABLE 12 U.S. compounding pharmacies market size, by solid preparation, 2017 - 2021 (USD Million)
TABLE 13 U.S. compounding pharmacies market size, by solid preparation, 2022 - 2030 (USD Million)
TABLE 14 U.S. compounding pharmacies market size, by liquid preparation, 2017 - 2021 (USD Million)
TABLE 15 U.S. compounding pharmacies market size, by liquid preparation, 2022 - 2030 (USD Million)
TABLE 16 U.S. compounding pharmacies market size, by topical, 2017 - 2021 (USD Million)
TABLE 17 U.S. compounding pharmacies market size, by topical, 2022 - 2030 (USD Million)
TABLE 18 U.S. compounding pharmacies market size, by rectal, 2017 - 2021 (USD Million)
TABLE 19 U.S. compounding pharmacies market size, by rectal, 2022 - 2030 (USD Million)
TABLE 20 U.S. compounding pharmacies market size, by parenteral, 2017 - 2021 (USD Million)
TABLE 21 U.S. compounding pharmacies market size, by parenteral, 2022 - 2030 (USD Million)
TABLE 22 U.S. compounding pharmacies market size, by application, 2017 - 2021 (USD Million)
TABLE 23 U.S. compounding pharmacies market size, by application, 2022 - 2030 (USD Million)
TABLE 24 U.S. compounding pharmacies market size, by compounding type, 2017 - 2021 (USD Million)
TABLE 25 U.S. compounding pharmacies market size, by compounding type, 2022 - 2030 (USD Million)
TABLE 26 U.S. compounding pharmacies market size, by therapeutic area, 2017 - 2021 (USD Million)
TABLE 27 U.S. compounding pharmacies market size, by therapeutic area, 2022 - 2030 (USD Million)